[{"id":"1bd3b65f-3d27-4d52-a00c-7ebcb1b64c6b","acronym":"KUNPENG","url":"https://clinicaltrials.gov/study/NCT04258033","created_at":"2021-01-18T20:41:41.946Z","updated_at":"2025-02-25T16:37:45.457Z","phase":"Phase 2","brief_title":"A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)","source_id_and_acronym":"NCT04258033 - KUNPENG","lead_sponsor":"Beijing Pearl Biotechnology Limited Liability Company","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 01/17/2020","start_date":" 01/17/2020","primary_txt":" Primary completion: 05/14/2024","primary_completion_date":" 05/14/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"dab562b9-279d-4fe8-b2fc-7ee0c721ed02","acronym":"KUNPENG-2","url":"https://clinicaltrials.gov/study/NCT05989542","created_at":"2023-08-14T14:10:14.391Z","updated_at":"2025-02-25T16:40:06.600Z","phase":"Phase 3","brief_title":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","source_id_and_acronym":"NCT05989542 - KUNPENG-2","lead_sponsor":"Beijing Pearl Biotechnology Limited Liability Company","biomarkers":" EGFR • KRAS • ALK • MET • ROS1","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement","tags":["EGFR • KRAS • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 06/29/2023","start_date":" 06/29/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-06"},{"id":"829b11a8-2149-49a1-8445-bba09c622fc3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06739395","created_at":"2025-02-26T09:10:09.582Z","updated_at":"2025-02-26T09:10:09.582Z","phase":"Phase 2","brief_title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","source_id_and_acronym":"NCT06739395","lead_sponsor":"Tianjin Medical University Second Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Focus V (anlotinib) • temozolomide • Lenvima (lenvatinib) • Piqray (alpelisib) • pazopanib • Epidaza (chidamide) • Trodelvy (sacituzumab govitecan-hziy) • vebreltinib (APL-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-12-18"},{"id":"3c7531a5-d2c1-4a20-9990-f4c698763dbe","acronym":"SPARTA","url":"https://clinicaltrials.gov/study/NCT03175224","created_at":"2022-05-11T08:56:01.997Z","updated_at":"2024-07-02T16:35:04.401Z","phase":"Phase 2","brief_title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","source_id_and_acronym":"NCT03175224 - SPARTA","lead_sponsor":"Apollomics Inc.","biomarkers":" HGF • PTPRZ1","pipe":" | ","alterations":" EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion","tags":["HGF • PTPRZ1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101) • CBT101"],"overall_status":"Recruiting","enrollment":" Enrollment 497","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-05-10"},{"id":"eedbe480-d689-4f15-9445-e03ffa8b99f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04743505","created_at":"2021-02-08T13:52:23.416Z","updated_at":"2024-07-02T16:35:07.638Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04743505","lead_sponsor":"Washington University School of Medicine","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • vebreltinib (APL-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/18/2022","start_date":" 01/18/2022","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2024-04-25"},{"id":"97e62d22-5c2a-48cf-89a8-1d7fd9cf36d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02978261","created_at":"2022-05-20T04:57:27.170Z","updated_at":"2024-07-02T16:36:49.173Z","phase":"Phase 1","brief_title":"Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas","source_id_and_acronym":"NCT02978261","lead_sponsor":"Beijing Pearl Biotechnology Limited Liability Company","biomarkers":" PTPRZ1","pipe":"","alterations":" ","tags":["PTPRZ1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2020-03-04"},{"id":"4cc8265e-4205-4bd2-973f-59ca6075ca1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02896231","created_at":"2021-01-17T17:43:49.245Z","updated_at":"2024-07-02T16:36:53.310Z","phase":"Phase 1","brief_title":"First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001","source_id_and_acronym":"NCT02896231","lead_sponsor":"Beijing Pearl Biotechnology Limited Liability Company","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2019-11-22"}]